- Home
- / Seagen
Seagen
Stock Price
$199.8
2023-08-25
Market Capitalization
$37.5 B
2023-08-25
Revenue
$2 B
FY, 2022
Seagen Summary
Company Summary
- Overview
- Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. It offers ADCETRIS for the treatment of certain CD30-expressing lymphomas; PADCEV for the treatment of certain metastatic urothelial cancers; TUKYSA for the treatment of certain metastatic HER2-positive breast cancers; and TIVDAK for the treatment of certain metastatic cervical cancers.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- Bothell, WA, US | view all locations
- Website
- https://www.seagen.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Roger Dansey, President, Research and Development
Vaughn Himes, Chief Technical Officer
Todd Simpson, Chief Financial Officer
LocationsView all
11 locations detected
Bothell, WA HQ
United States
21717 30th Drive S.E., Building 3
Bothell, WA
United States
21823 30th Drive S.E.
Mississauga, ON
Canada
2000 Argentia Road Plaza 3, Suite 400
Hørsholm
Denmark
Agern Alle 24
Rueil-Malmaison, IDF
France
55 Av. de Colmar
München, BY
Germany
Maximilianstr. 13, 3rd floor
Seagen Financials
Summary Financials
- Revenue (Q2, 2023)
- $603.8M
- Gross profit (Q2, 2023)
- $423.1M
- Net income (Q2, 2023)
- ($211.5M)
- Cash (Q2, 2023)
- $308.4M
- EBIT (Q2, 2023)
- ($220.7M)
- Enterprise value
- $37.3B